585 related articles for article (PubMed ID: 34669432)
1. mRNA Vaccines in the COVID-19 Pandemic and Beyond.
Hogan MJ; Pardi N
Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432
[TBL] [Abstract][Full Text] [Related]
2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
4. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT; Mahiny AJ; Vlatkovic I
Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
[TBL] [Abstract][Full Text] [Related]
6. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
7. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
8. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
9. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.
Hajissa K; Mussa A
Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862
[TBL] [Abstract][Full Text] [Related]
10. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2: vaccines in the pandemic era.
Li DD; Li QH
Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
[TBL] [Abstract][Full Text] [Related]
12. Development of vaccines for SARS-CoV-2.
Ng WH; Liu X; Mahalingam S
F1000Res; 2020; 9():. PubMed ID: 32850116
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
14. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
Front Public Health; 2021; 9():778964. PubMed ID: 34888290
[No Abstract] [Full Text] [Related]
15. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
16. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 and vaccination: myths vs science.
Chavda VP; Chen Y; Dave J; Chen ZS; Chauhan SC; Yallapu MM; Uversky VN; Bezbaruah R; Patel S; Apostolopoulos V
Expert Rev Vaccines; 2022 Nov; 21(11):1603-1620. PubMed ID: 35980281
[TBL] [Abstract][Full Text] [Related]
18. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
[TBL] [Abstract][Full Text] [Related]
19. Advances in COVID-19 mRNA vaccine development.
Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]